BPC-157 is probably the most casually recommended compound in the entire peptide world, passed along in gym conversations and injury threads like a supplement. The evidence reality is thinner than the reputation: roughly thirty humans have ever received it across a handful of small studies, which is the core of why the FDA moved against it. What BPC-157 does have is data of a different kind. With 925 published third-party tests across 147 tracked vendors, it holds the deepest testing record of any non-GLP-1 compound in our index, and that record is what this guide reads.
For years, med spas and longevity clinics sold BPC-157 through compounding pharmacies, which gave it a paradoxical air of legitimacy for an unapproved drug. That ended in September 2023, when the FDA placed BPC-157 in Category 2 of its compounding bulks list, citing immunogenicity risk and impurity concerns, a designation that bars licensed pharmacies from preparing it. The agency has revisited peptide compounding policy since, but as of this writing the bar stands. Unlike tirzepatide or semaglutide, there is no branded product to fall back on, and unlike retatrutide, there is no big trial program working toward one. The research-chemical market is not the gray edge of this compound’s world; it is the entire map.
Three patterns stand out on the BPC-157 leaderboard. First, prices sit in a tight band: the current top eight scored vendors publish $0.60 to $1.00 per milligram, nothing like the 15x and 28x spreads we track on PT-141 and semaglutide. A decade of demand has made this a commodity market where competition polices price. Second, scores are moderate rather than stellar, running 62 to 77 at the top even on records of nine to twenty-two tests. Quantity misses on a cheap compound are the usual culprit. Third, the record is current, with leader dates from June through August 2026, so unlike some boards we cover, staleness is not the problem here. The work is picking a vendor whose specific recent batches verified, which the leaderboard’s source links let you do in a few clicks.
A large share of BPC-157 buyers are really buying half of the wolverine stack. If that is you, the stack guide covers the pairing logic and its evidence gaps, and one point bears repeating from the buying side: two compounds mean two labels that can each be wrong, so a stack purchase is two verification jobs, not one.
Find the vendor on the leaderboard and open their published tests. Confirm there is a certificate for the specific batch you would receive, not a generic purity claim. Check the certificate verifies on the issuing lab’s own site (our verification guide shows how in under a minute). Look at measured quantity, since a 10mg label over a 7mg fill is the most common way this compound disappoints. Then check the date against what you are being shipped. At $0.60 to $1.00 per milligram for verified material, anything dramatically cheaper is answering a question you did not ask.
It is sold as a research chemical in the usual not-for-human-use frame. What changed in 2023 is the clinic route: compounding it is barred, so any med spa still offering “prescription BPC-157” is operating against the FDA’s published position.
Yes. WADA prohibits it as an unapproved substance, and it has appeared in supplement-contamination warnings aimed at athletes. Tested competitors should treat it as a positive result waiting to happen.
Mostly fill accuracy. The compound is cheap to synthesize, but our scoring weighs measured quantity against the label, and underfills are common enough here to hold the whole board in the 60s and 70s. The per-vendor records are deep, so the scores are earned rather than artifacts of thin data.
Oral products exist and are marketed on the claim that the molecule survives the gut. Published third-party testing of capsules is far scarcer than for vials, which by this site’s standards makes them the less verifiable format, whatever the mechanism arguments say.
Verified vendors cluster between $0.60 and $1.00 per milligram as of September 2026. Compare on tested content, and run the reconstitution numbers through the calculator once a verified vial is actually in hand.
BPC-157’s popularity runs years ahead of its human evidence, and no guide changes that. What the published record can do is tell you whether the vial you are about to order matches its label. Start at the compound page, check the batch, and treat every claim you cannot click through to a lab document as decoration.
PeptideCensus Editorial is the research team behind the independent peptide lab-result index. Every article is built from published third-party data - trial publications, lab reports, and regulatory records - with every number linked to its source. We don't test, we don't sell, and commissions never touch scores or rankings.
About PeptideCensus →